Neuroleptic malignant syndrome is a rare, idiosyncratic, and potentially fatal neurologic emergency triggered by the administration of dopamine receptor antagonists or the abrupt withdrawal of dopaminergic medications^{1, 2}. First recognized in association with potent typical antipsychotics, the syndrome is characterized by a constellation of cardinal clinical features including severe hyperthermia, extreme lead-pipe muscle rigidity, autonomic nervous system instability, and fluctuating encephalopathy⁶. Because mortality ranges from 5% to over 20% if left unrecognised, rapid clinical identification, immediate cessation of the offending agent, and aggressive multidisciplinary supportive intensive care are mandatory for survival^{4, 6}.

1. Etiology & Risk Factors

• Typical (First-Generation) Antipsychotics: High-potency agents such as haloperidol, fluphenazine, and chlorpromazine carry the highest individual risk due to potent blockade of central postsynaptic dopamine D2 receptors^{2, 7}.
• Atypical (Second-Generation) Antipsychotics: Agents including olanzapine, risperidone, quetiapine, and aripiprazole can induce the syndrome, often with less prominent rigidity or lower absolute frequency, though atypical presentations are increasingly documented^{4, 7}.
• Dopaminergic Withdrawal: Sudden cessation, dose reduction, or withdrawal of antiparkinsonian medications (such as levodopa, carbidopa, or dopamine agonists like ropinirole and pramipexole) in patients with Parkinson's disease can precipitate an identical akinetic hyperthermic state¹.
• Dopaminergic Antiemetics: Metoclopramide, promethazine, and droperidol block central and peripheral dopamine receptors and have repeatedly been implicated in acute iatrogenic presentations¹.
• Patient-Specific Risk Factors: High ambient temperatures, physical exhaustion, severe dehydration, acute organic brain injury, iron deficiency anaemia, prior episodes of neuroleptic malignant syndrome, and rapid escalation of antipsychotic doses significantly increase individual susceptibility⁶.

2. Pathophysiology

The primary pathophysiological driver of neuroleptic malignant syndrome is the profound and rapid blockade of central dopamine D2 receptors within the corpus striatum, hypothalamus, and mesolimbic pathways^{1, 2}. Blockade of striatal dopaminergic transmission leads to excessive outflow of uninhibited gamma-aminobutyric acid (GABA) and acetylcholine, resulting in sustained skeletal muscle contraction, increased metabolic rate, heat production, and lead-pipe rigidity². Simultaneously, impairment of hypothalamic thermoregulatory control centers disrupts normal heat-dissipation mechanisms via cutaneous vasodilation and sweating, driving core body temperatures to dangerous hyperpyrexic levels⁶. The sustained, rigid muscular activity outstrips oxygen and ATP supply, leading to cellular hypoxia, adenosine triphosphate depletion, sarcolemmal membrane destruction, and massive leakage of intracellular skeletal muscle contents—such as creatine kinase, potassium, myoglobin, and lactate dehydrogenase—into the systemic circulation, which frequently culminates in acute rhabdomyolysis and acute kidney injury^{1, 4}.

3. Clinical Presentation & Classic Clinical Signs

• History & Cardinal Symptoms: The syndrome typically evolves over 24 to 72 hours following the initiation, dose increase, or switch of a causative dopamine antagonist, or within hours of dopaminergic drug withdrawal^{1, 6}. Patients initially present with a triad or tetrad of rapidly progressive symptoms: altered mental status, autonomic lability, hyperthermia, and motor abnormalities⁶.
• Physical Examination & Named Clinical Signs:
  • Encephalopathy: Ranges from mild confusion, agitation, and catatonia to profound stupor, mutism, and unresponsiveness ("waxy flexibility")⁶.
  • Hyperthermia: Core body temperature characteristically exceeds 38.5°C and can rise to profound levels (40°C to 42°C), predisposing to heat stroke and multiorgan failure³.
  • Muscle Rigidity: Generalized, severe, lead-pipe rigidity is classic. Regular or sawtooth cogwheeling may be present, accompanied by severe generalized myalgia, tremors, and dysphagia⁶.
  • Autonomic Instability: Marked blood pressure lability, labile tachycardia, tachypnea, profuse diaphoresis, urinary incontinence, and cutaneous pallor or flushing reflect autonomic nervous system dysfunction³.
  • Reflex Profile: Deep tendon reflexes are typically normal or diminished (hyporeflexia), providing a crucial clinical discriminator from serotonin syndrome³.

4. Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

5. Staging, Classification & Clinical Scoring Systems

6. Differential Diagnosis

7. Management & Treatment Protocol

• Initial Stabilization & Resuscitation: Immediately discontinue all causative dopamine-blocking antipsychotic agents or reinstate dopaminergic therapy if withdrawal-induced^{1, 6}. Transfer the patient to an Intensive Care Unit (ICU) for continuous hemodynamic monitoring, airway protection in obtunded states, and aggressive core temperature reduction using cooling blankets, ice packs, and evaporative cooling⁶.
• First-Line Medical / Pharmacological Therapy (with exact adult dosing):
  • Supportive Hydration: Aggressive intravenous fluid resuscitation with normal saline to maintain adequate urine output (>2 mL/kg/h) and alkalinization of urine to prevent acute tubular necrosis from myoglobinuria⁶.
  • Dantrolene: A direct-acting skeletal muscle relaxant that inhibits calcium ion release from the sarcoplasmic reticulum. Administer intravenous dantrolene at an initial adult loading dose of 1.0 to 2.5 mg/kg IV, repeated as necessary up to a maximum cumulative dose of 10 mg/kg/day until rigidity and hyperthermia subside^{4, 6}.
  • Bromocriptine: A central dopamine D2 receptor agonist. Administer oral bromocriptine at an initial dose of 2.5 mg PO every 8 hours, titrated upward gradually up to 10 to 20 mg PO every 8 hours (maximum 40 mg/day) to overcome central dopamine blockade^{1, 6}.
  • Amantadine: Alternative dopaminergic agonist administered at 100 to 200 mg PO or enteral tube every 12 hours if bromocriptine is unavailable¹.
  • Benzodiazepines: Lorazepam (1 to 2 mg IV every 4 to 8 hours) is frequently utilised to control agitation, catatonia, and mild muscle rigidity¹.
• Surgical / Interventional Indications: Continuous renal replacement therapy (CRRT) or hemodialysis is indicated if severe rhabdomyolysis induces refractory acute kidney injury, severe hyperkalemia, or profound fluid overload⁶. Mechanical ventilation and endotracheal intubation are required for patients with bulbar dysfunction, severe encephalopathy, or respiratory failure⁶.

8. Complications & Prognosis

• Acute Complications: Rhabdomyolysis, acute kidney injury requiring renal replacement therapy, aspiration pneumonia, pulmonary embolism, deep vein thrombosis, disseminated intravascular coagulation (DIC), cardiac arrhythmias, hypoxic encephalopathy, and multiorgan dysfunction syndrome^{1, 6}.
• Mortality & Recovery: With prompt recognition and modern intensive care management, overall mortality has declined from historical highs of over 20% to approximately 5% to 10%^{4, 5}. Complete recovery typically occurs within 7 to 14 days following oral agent cessation, though catatonic symptoms or subtle cognitive deficits can persist for weeks⁶.
• Rechallenge Considerations: If psychiatric continuation requires antipsychotic therapy following complete resolution of neuroleptic malignant syndrome, clinicians should wait at least 2 weeks before cautious rechallenge, utilize low-potency atypical agents, avoid rapid titration, and monitor closely for early recurrence⁴.